[et_pb_section fb_built=\u00bb1″ _builder_version=\u00bb4.27.0″ custom_margin=\u00bb-39px||||false|false\u00bb custom_margin_tablet=\u00bb-39px||||false|false\u00bb custom_margin_phone=\u00bb-40px||||false|false\u00bb custom_margin_last_edited=\u00bbon|phone\u00bb custom_padding=\u00bb0px||0px||false|false\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbet_body_layout\u00bb][et_pb_row _builder_version=\u00bb4.16″ background_size=\u00bbinitial\u00bb background_position=\u00bbtop_left\u00bb background_repeat=\u00bbrepeat\u00bb width=\u00bb84.5%\u00bb global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbet_body_layout\u00bb][et_pb_column type=\u00bb4_4″ _builder_version=\u00bb4.16″ custom_padding=\u00bb|||\u00bb global_colors_info=\u00bb{}\u00bb custom_padding__hover=\u00bb|||\u00bb theme_builder_area=\u00bbet_body_layout\u00bb][et_pb_text _builder_version=\u00bb4.27.4″ background_size=\u00bbinitial\u00bb background_position=\u00bbtop_left\u00bb background_repeat=\u00bbrepeat\u00bb custom_margin=\u00bb17px||||false|false\u00bb hover_enabled=\u00bb0″ global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbet_body_layout\u00bb sticky_enabled=\u00bb0″]<\/p>\n
LAB+ Company Builder y el Institut Pasteur de Montevideo dijeron presente en el Foro Biotech 2025, organizado por la Universidad ORT Uruguay en el Laboratorio Tecnol\u00f3gico del Uruguay (LATU).<\/span><\/strong><\/span><\/p>\n <\/p>\n El foro, que este a\u00f1o tuvo su segunda edici\u00f3n, re\u00fane a referentes del \u00e1rea de la biotecnolog\u00eda, as\u00ed como a estudiantes e interesados en el \u00e1rea<\/p>\n <\/p>\n Diego Melazzi, director ejecutivo de FICUS Advisory<\/a>, particip\u00f3 en la mesa redonda \u00abInversiones en Biotech\u00bb, para hablar de LAB+.<\/p>\n <\/p>\n Claudia Vanesa Piattoni, gerenta de Innovaci\u00f3n del instituto y de LAB+, expuso sobre el trabajo del IP y su relaci\u00f3n con la biotecnolog\u00eda.<\/p>\n [\/et_pb_text][et_pb_image src=\u00bbhttps:\/\/labplus.uy\/wp-content\/uploads\/2025\/10\/biotech-forum-vanesa.jpg\u00bb title_text=\u00bbbiotech forum vanesa\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb hover_enabled=\u00bb0″ global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbet_body_layout\u00bb sticky_enabled=\u00bb0″][\/et_pb_image][et_pb_text _builder_version=\u00bb4.27.4″ background_size=\u00bbinitial\u00bb background_position=\u00bbtop_left\u00bb background_repeat=\u00bbrepeat\u00bb custom_margin=\u00bb17px||||false|false\u00bb hover_enabled=\u00bb0″ global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbet_body_layout\u00bb sticky_enabled=\u00bb0″]<\/p>\n En tanto, Mat\u00edas Machado, cofundador de Scaffold Biotech<\/a>, habl\u00f3 sobre la vacuna contra la garrapata que desarrolla la startup.<\/p>\n [\/et_pb_text][et_pb_image src=\u00bbhttps:\/\/labplus.uy\/wp-content\/uploads\/2025\/10\/biotech-forum-matias.jpg\u00bb _builder_version=\u00bb4.27.4″ _module_preset=\u00bbdefault\u00bb theme_builder_area=\u00bbet_body_layout\u00bb title_text=\u00bbbiotech forum matias\u00bb hover_enabled=\u00bb0″ sticky_enabled=\u00bb0″][\/et_pb_image][et_pb_text _builder_version=\u00bb4.27.4″ background_size=\u00bbinitial\u00bb background_position=\u00bbtop_left\u00bb background_repeat=\u00bbrepeat\u00bb custom_margin=\u00bb17px||||false|false\u00bb hover_enabled=\u00bb0″ global_colors_info=\u00bb{}\u00bb theme_builder_area=\u00bbet_body_layout\u00bb sticky_enabled=\u00bb0″]<\/p>\n